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The Regulatory Biology of Humanism 
 
There is little doubt that humans are the masters of their 
known universe. A lively debate could center on why 
this is so. Although humans have many specialized 
physical features, such as the marvelous human hand 
and fingers, other species also have distinguishing 
features that outclass similar physical features of 
humans - features such as more acute hearing, smell, or 
sight. There is little debate, however, that our crowning 
evolutionary achievement is the human brain. There 
appears to be no species or other mammal capable of 
competing with our ability to reason, plan, calculate, 
and emote. How did this impressive jump in evolution 
occur? Although not a question that can be answered by 
hard data, it remains a lively topic for discussion. In my 
opinion, the two most advanced biologic ‘systems’ that 
we humans have are (1) the central and peripheral 
endocrine system and (2) the cellular proteome. It is 
these two points I would like to further develop in this 
Perspective.   
 
Our endocrine system and our cellular proteome form 
an intimate connection with the human brain to 
construct a powerful troika responsible for our unique 
capacities as a species.  This partnership likely co-
evolved to cope with the diversity of our environment 
and with the intense metabolic demands required to 
nurture, operate and preserve the human brain. 
Hormones comprise the endocrine system. The word 
itself emanates from the Latin word ‘hormo’ which 
means to ‘set in motion’. Hormones do that in great 
fashion, as they move all cells and organs of our body 
into action. Our cells and tissues would be relatively 
inert without them. These chemical regulators control 
our genesis, development, maturation, and then function 
in adulthood to support the growth  and metabolic  func- 
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tions of all organs, including the brain and its peripheral 
links. Hormones are not unique to humans, however. 
They exist even in plants, worms and flies. Mammals, 
however, have a more highly developed endocrine 
system that contains many specialized hormones. It is 
uncertain as to how many hormones actually exist in 
mammals. We often list ~50 of the more common 
hormones, but the actual numbers likely are in the 
hundreds, and perhaps will reach closer to a thousand 
when finally all are identified. At an earlier period in 
the field of Endocrinology, we defined hormones as 
‘chemical signals released from an organ into the blood 
stream to act on distant target tissues. Clearly, this 
definition has been outdated for some years, and a 
compete list of hormones probably should include a 
variety of paracrine and autocrine chemical signals, 
including growth factors, immune cell secretions, 
cytokines, chemokines, and perhaps even neuro-
transmitters. There is no greater diversity of 
environmental signals and physical and emotional 
stresses for a mammal to bear than those to which a 
human being has been subjected over the course of 
evolution. 
  
Although humans have a limited number of unique 
hormones compared to other mammals, it is our ability 
to respond in a more complex fashion to our hormones 
that distinguishes us from other mammals. It is not the 
number of individual factors but the complexity of 
combinations that provides our ‘human advantage’. For 
example, does the total number of keys on a piano 
provide the complexity to create music, or is it the 
combinatorial fashion in which the keys are activated by 
the pianist’s fingers. For humans, is the evolutionary 
advantage we have savored due to the total number of 
genes we have? Clearly not, as we have virtually the 
same number of genes as a worm, with current 
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Consequently, the number of human genes is 
insufficient to distinguish us from species as distant as 
fungi or flies. Can the existence of RNA splicing 
provide sufficient proteomic complexity to distinguish 
the mammalian species? It appears not. Although 
humans can splice our genes in five different ways on 
average, allowing a total of ~125,000 gene products 
across the genome, worms and flies also can splice their 
RNAs similarly. How then did mammals achieve the 
number of combinations of cell signaling events 
required for the immense complexity that we have 
achieved? Furthermore, how are we likely to continue 
to evolve in the very distant future? I believe that the 
answer to this question lies in our cells’ proteomes, and 
more specifically, in its associated complex signaling 
pathways. 
 
Perhaps the most defining molecular characteristic of 
mammals is the greater number of transcriptional 
coregulators that they possess compared to other 
species. Our studies in the nuclear receptor field have 
uncovered a class of new transcriptional regulatory 
molecules termed coregulators, emanating from our 
initial cloning of SRC-1 (Steroid Receptor Coactivator-
1 [1]. Coregulators are composed of coactivators which 
provide positive enhancement to gene expression, and 
corepressors which suppress gene expression. 
Coactivators are regulatory molecules that are recruited 
to genes by DNA-binding transcription factors, and 
provide the ability to fine-tune our genes and activate 
them in combinations [2]. In this Perspective, we will 
focus exclusively on our own lab’s contributions and on 
my opinions for the coactivator field, emphasizing the 
roles of three members of the SRC-family of 
coactivators. 
 
Recently, we have come to realize that coactivators are 
the likely ‘master regulators’ of our genome, capable of 
coordinately activating subgroups of genes that might 
be required for a specific physiologic process such as 
growth, reproduction, inflammation, or metabolism 
[14]. DNA-binding transcription factors, such as nuclear 
receptors, bind nearby to genes and mark them for 
activation or repression, functions subsequently effected 
by the recruitment of coregulators. Worms or flies have 
few coactivators compared to mammals. Currently, over 
350 coregulators have been identified in mammals in 
the literature (www.NURSA.org). This number may 
eventually reach to ~500 or so, given that coactivators 
and corepressors only have been discovered as a class 
of molecules for 1.5 decades. We now understand that 
coactivators act in functional complexes of ~6-12 
proteins [3]. This multiplicity of proteins, operating in 
an active complex, provides great complexity in 
function due to the large variety of combinations into 
which different coactivator proteins can assemble in a 
given coactivator complex [4]. In part, this vast 
proteomic complexity of transcriptional coactivators 
allows us a greater genomic complexity for responding 
to the large variety of environmental signals that 
impinge upon our cells. 
 
In the proteome, is it all about the primary protein 
backbones? Absolutely not! The greatest of all defining 
characteristics of the proteome is the vast number of 
posttranslational modifications (PTMs) that are 
superimposed upon our proteins [5]. These include such 
modifications as phosphorylations, ubiquitinations, 
sumoylations, methylations, acetylations, glycosyla-
tions, etc. We need only to accept the current popular 
hypothesis that every PTM added to a protein provides 
it ‘some new capability’ in order to understand the 
functional power of posttranslational modifications. 
When a new modification occurs on a protein, we may 
not be able to understand the precise cellular function of 
that PTM, but Darwinian logic tells us that if the 
modification is held constant in the species, then there 
must be some positive selective advantage for it. The 
combinatorial potential added to a protein by 
posttranslational modifications can be enormous. For 
example, the coactivator, SRC-3, contains over 50 
distinct PTMS. This provides an enormous ‘potential’ 
combinatorial capacity. Consider this theoretical 
example. If a protein contains 40 PTMs, it has a 
combinatorial ‘potential’ of (2)
40, amounting to >1x10
12  
possible combinations [3,6]. Although I am certain that 
this enormous potential is never reached, my point on 
the magnitude of potential possibilities is clear; PTMs 
provide an enormous jump in coactivator protein 
complexity. Moreover, when we calculate an additional 
complexity due to the fact that 6-12 proteins work 
together in combination in a coactivator complex, the 
numbers reach astronomical proportions. In fact, we 
probably will never know the true complexity of the 
mammalian proteome, but it is certainly ‘light years’ 
beyond what is directly possible from the genome. It is 
this PTM complexity that imparts the capacity to 
coactivators to regulate so many diverse cellular 
reactions, some of which even occur outside the nucleus 
[3,7].  
 
Although the existence of PTM-controlled coactivators 
might explain the combinatorial diversity of function 
required for the superior metabolism and brain power of 
mammals, one might question why the mouse is not 
able to function as well as a human when it contains 
most of the coactivators that have been described in 
humans. We can only speculate as to the precise 
explanation, but it appears that humans have more 
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been reported to have ~4-5 more protein (coactivator)  
phophorylations than do mice [8]. Although 4 more 
PTMs may not be overly impressive at first glance, this 
number provides 16-fold more combinatorial potential 
per protein, and since each coactivator protein works in 
a complex with 6-12 other proteins, the factorial 
calculation of combinations in the complex quickly 
becomes exponentially large. Also, while it is accepted 
that rodents can potentially avail themselves to some 
PTM complexity, their nervous system is not 
structurally prepared to make full use of PTM 
complexity as can we humans.  It should be 
remembered that phosphorylation is only one type of 
PTM modification among many that occur commonly 
on proteins. There is no doubt that the human brain (and 
organs) requires large regulatory complexity, and it is 
most certainly available in the potential of the 
proteome.  One might surmise that in our entire future 
evolution, we will never have a need for a new gene, 
since a new function could be acquired simply by 
adding a novel PTM to an existing protein.  
 
Although humans may owe a part of their evolved 
capacity as ‘masters of their universe’ to their cadre of 
‘master gene’ products, such as the mammalian 
coregulators, this considerable regulatory advantage 
comes at a price. Disease processes are prone to co-opt 
coactivators for their own purposes because they can 
provide ‘one-stop’ shopping for control of vast numbers 
of genes that support their pathologic goals. There is no 
greater example of this than that provided by the cancer 
cell. A large variety of cancers over-express SRC-3 to 
promote their relentless growth, including breast, lung, 
pancreatic, prostate, intestinal and ovarian cancers [9]. 
Cancers that over-express this coactivator grow more 
aggressively and are more resistant to therapy. 
Similarly, SRC-1 has been recently revealed to be a 
coactivator that promotes tumor metastases [10]. 
Simultaneous over-expression of both SRC-3 and SRC-
2 marks a tumor as particularly dangerous and more 
likely to recur after therapy.  
 
Metabolism is another major focus of coactivator 
action. PGC-1 was the first coactivator to be shown by 
the Spiegelman lab to have metabolic regulatory 
functions. Recently, we published that the coactivator, 
SRC-2, is a master gene for energy accretion and 
storage. When ATP levels in cells drop, SRC-2 is 
activated by AMP kinase, and SRC-2 then stimulates 
the liver to secrete bile to the intestine in order to absorb 
fat from the diet [11]. When the SRC-2 gene is deleted, 
animals cannot absorb fat efficiently, and cannot store it 
well. SRC-2 also regulates glucose release from the 
liver [12]. Thus, this coactivator acts as a sensor for 
energy accretion, whereby a drop in cellular energy 
(ATP), leads to an increase in fat (caloric) absorption to 
replenish whole body energy levels. The SRC-2 
coactivator was likely a major advantage for early 
humans (and mammals) because of their critical need 
for food, a scarce commodity. Their caloric intake was 
accomplished best via efficient fat ingestion and 
storage. In present times, however, with the 
availability of fast food on most urban corners, SRC-
2’s efficiency has now become disadvantageous. In 
any event, these examples serve to substantiate the 
important roles coactivators play in our metabolic 
systems biology [13]. 
 
Surprisingly, there are very few studies to date on the 
effects of coactivator dysfunction on the aging process. 
Observations show that animals with coactivator 
mutations do not age well, and that early death is more 
common. Certain alterations in the metabolism with 
genetically altered coactivators are similar to the aging 
human. Nevertheless, the lack of experimental studies 
limits our knowledge of their specific roles. This area of 
investigation speaks out for more future investigative 
attention. 
 
In summary, during the past 15 years, we have 
identified a large new class of regulators, the 
coactivators/corepressors [14]. A good deal has been 
learned about their mechanisms of action and their 
immense physiologic and pathologic relevance. In fact, 
studies of coactivators may prove key to unlocking the 
mysteries of polygenic diseases [15]. Now, the 
challenge arises for us to harness them for therapeutic 
purposes. Already, they have been demonstrated to have 
diagnostic and prognostic value for cancers [9]. The 
question remains as to how we might design a new class 
of drugs that would regulate these ‘regulators’. Early 
and mostly unpublished experimental data is 
encouraging in this respect. Nevertheless, the future will 
provide a final answer as to whether a new type of 
pharmacologic intervention at the coactivator level can 
be utilized for therapies of human diseases. 
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